Search research articles
Contact Us
Filters
Showing results (11-20 of 36) with videos related to
Page
of 4
Sort By:
Journal of Clinical Pharmacology
|
May 9, 2024
Guiding Dyslipidemia Treatment: A Population Pharmacokinetic-Pharmacodynamic Framework for Obicetrapib
Allison Dunn, Marc Ditmarsch, John J P Kastelein, et al.
European Heart Journal. Cardiovascular Pharmacotherapy
|
October 29, 2022
Comparison of low-density lipoprotein cholesterol equations in patients with dyslipidaemia receiving cholesterol ester transfer protein inhibition
Seth S Martin, Marc Ditmarsch, Mark Simmons, et al.
International Journal of Molecular Sciences
|
August 26, 2022
Cholesteryl Ester Transfer Protein Inhibition Reduces Major Adverse Cardiovascular Events by Lowering Apolipoprotein B Levels
Adam J Nelson, Allan D Sniderman, Marc Ditmarsch, et al.
Nature Medicine
|
August 11, 2022
Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial
Stephen J Nicholls, Marc Ditmarsch, John J Kastelein, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions
|
June 26, 2025
A Drug-Drug Interaction Study Evaluating the Pharmacokinetic Consequences of Obicetrapib Therapy on Atorvastatin or Rosuvastatin Levels in Healthy Volunteers
John J P Kastelein, Marc Ditmarsch, Andrew Hsieh, et al.
American Journal of Preventive Cardiology
|
April 20, 2026
The emerging role of CETP inhibition in the prevention of Alzheimer's disease
Michael H Davidson, Andrew Hsieh, Mathijs de Kleer, et al.
European Heart Journal
|
May 25, 2026
Obicetrapib and lipoprotein(a) levels in patients at high cardiovascular risk: a pooled analysis of trials
Stephen J Nicholls, Adam J Nelson, Kausik K Ray, et al.
European Journal of Preventive Cardiology
|
December 24, 2025
Efficacy of Obicetrapib Across the Spectrum of Background Lipid-Lowering Therapies: Pooled Analyses of the BROADWAY and BROOKLYN Randomized Trials
Fotios Barkas, Michael Szarek, Adam J Nelson, et al.
Journal of Clinical Pharmacology
|
August 19, 2024
A Randomized, Parallel, Open-Label, Single-Dose and Multiple-Dose Clinical Trial to Investigate the Pharmacokinetic, Pharmacodynamic, and Safety Profiles of Obicetrapib in Healthy Participants in China
Jing Zhang, Guoying Cao, Yong Huo, et al.
American Heart Journal
|
June 22, 2015
Effects of the dual peroxisome proliferator-activated receptor activator aleglitazar in patients with Type 2 Diabetes mellitus or prediabetes
Erland Erdmann, Robert Califf, Hertzel C Gerstein, et al.
Page
of 4
Search research articles
Search
Showing results (11-20 of 36) with videos related to
Sort By:
Page
of 4
Journal of Clinical Pharmacology
|
May 9, 2024
Guiding Dyslipidemia Treatment: A Population Pharmacokinetic-Pharmacodynamic Framework for Obicetrapib
Allison Dunn, Marc Ditmarsch, John J P Kastelein, et al.
European Heart Journal. Cardiovascular Pharmacotherapy
|
October 29, 2022
Comparison of low-density lipoprotein cholesterol equations in patients with dyslipidaemia receiving cholesterol ester transfer protein inhibition
Seth S Martin, Marc Ditmarsch, Mark Simmons, et al.
International Journal of Molecular Sciences
|
August 26, 2022
Cholesteryl Ester Transfer Protein Inhibition Reduces Major Adverse Cardiovascular Events by Lowering Apolipoprotein B Levels
Adam J Nelson, Allan D Sniderman, Marc Ditmarsch, et al.
Nature Medicine
|
August 11, 2022
Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial
Stephen J Nicholls, Marc Ditmarsch, John J Kastelein, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions
|
June 26, 2025
A Drug-Drug Interaction Study Evaluating the Pharmacokinetic Consequences of Obicetrapib Therapy on Atorvastatin or Rosuvastatin Levels in Healthy Volunteers
John J P Kastelein, Marc Ditmarsch, Andrew Hsieh, et al.
American Journal of Preventive Cardiology
|
April 20, 2026
The emerging role of CETP inhibition in the prevention of Alzheimer's disease
Michael H Davidson, Andrew Hsieh, Mathijs de Kleer, et al.
European Heart Journal
|
May 25, 2026
Obicetrapib and lipoprotein(a) levels in patients at high cardiovascular risk: a pooled analysis of trials
Stephen J Nicholls, Adam J Nelson, Kausik K Ray, et al.
European Journal of Preventive Cardiology
|
December 24, 2025
Efficacy of Obicetrapib Across the Spectrum of Background Lipid-Lowering Therapies: Pooled Analyses of the BROADWAY and BROOKLYN Randomized Trials
Fotios Barkas, Michael Szarek, Adam J Nelson, et al.
Journal of Clinical Pharmacology
|
August 19, 2024
A Randomized, Parallel, Open-Label, Single-Dose and Multiple-Dose Clinical Trial to Investigate the Pharmacokinetic, Pharmacodynamic, and Safety Profiles of Obicetrapib in Healthy Participants in China
Jing Zhang, Guoying Cao, Yong Huo, et al.
American Heart Journal
|
June 22, 2015
Effects of the dual peroxisome proliferator-activated receptor activator aleglitazar in patients with Type 2 Diabetes mellitus or prediabetes
Erland Erdmann, Robert Califf, Hertzel C Gerstein, et al.
Page
of 4